RU 28318

Also Known As:

17 beta-hydroxy-3-oxo-7 alpha-propyl(17 alpha)pregn-4-ene-21-carboxylate potassium salt; RU-28318; Pregn-4-ene-21-carboxylic acid, 17-hydroxy-3-oxo-7-propyl-, monopotassium salt, (7alpha,17alpha)-

Networked: 12 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Lactones: 1549
  - Spironolactone: 3235
    - RU 28318: 12
Polycyclic Compounds: 6
- Fused-Ring Compounds
  - Steroids: 70059
    - Pregnanes: 9
      - Pregnenes: 1
        Spironolactone: 3235
        RU 28318: 12

Experts

1.	Gravenstein, Nikolaus: 2 articles (01/2016 - 02/2015)
2.	Xu, Changqing: 2 articles (01/2016 - 02/2015)
3.	Martynyuk, Anatoly E: 1 article (01/2016)
4.	Puentes, Dyanet L: 1 article (01/2016)
5.	Seubert, Christoph N: 1 article (01/2016)
6.	Zhang, Jiaqiang: 1 article (01/2016)
7.	Martynyuk, Anatoly: 1 article (02/2015)
8.	Perez-Downes, Julio: 1 article (02/2015)
9.	Seubert, Christoph: 1 article (02/2015)
10.	Tan, Sijie: 1 article (02/2015)

Related Diseases

1.	Hypertension (High Blood Pressure) 10/01/1984 - "Administration of an antimineralocorticoid derivative, RU 28318, did not modify hypertension. " 03/01/1985 - "In contrast administration of RU 28318, an antimineralocorticoid agent, was without effect on glucocorticoid hypertension (+38 mm Hg). " 12/01/1994 - "During the development of this hypertension (after 3 wk of DOCA-salt treatment) a single intracerebroventricular injection of the specific MR antagonist RU-28318 reduced systolic blood pressure (SBP) as measured with the tail-cuff method. " 12/01/1994 - "The role of brain mineralocorticoid receptor (MR) sites in the pathogenesis of mineralocorticoid hypertension was studied after an intracerebroventricular injection of the MR antagonist RU-28318. " 11/01/1990 - "The possibility that central mineralocorticoid binding sites are involved in the development of mineralocorticoid hypertension was examined using chronic blockade of these sites with a specific mineralocorticoid receptor antagonist RU 28318 administered by intracerebroventricular (icv) infusion. "
2.	Gynecomastia 07/01/1991 - "The observed rate of gynecomastia in the RU 28318 group, not statistically different from that in the spironolactone group, was in agreement with the results of others studies conducted at the same time and resulted in the discontinuation of the development of the molecule." 07/01/1991 - "During the follow-up period, 18 gynecomastia were observed, 7 in the RU 28318 group and 11 in the spironolactone group, after 4 to 5 months of treatment. "
3.	Seizures (Absence Seizure) 01/01/2016 - "These estradiol-enhanced seizures and spikes were depressed by ICI 182780 and the NKCC1 inhibitor, bumetanide, while RU 28318 decreased seizures only. " 02/01/2015 - "Mineralocorticoid and glucocorticoid receptor antagonists, RU 28318 and RU486, depressed electroencephalographic seizures but did not affect the spike electroencephalographic effects of propofol. " 01/01/2016 - "In the order of increasing potency, the corticosteroid receptor antagonist RU 28318, the estradiol receptor antagonist ICI 182780 and the estradiol synthesis inhibitor formestane decreased sevoflurane-induced seizures. "
4.	Ventricular Premature Complexes (Premature Ventricular Contraction) 01/01/2015 - "Conversely, potassium canrenoate 100 nmol/L and RU 28318 1 μmol/l alone did not affect AP parameters and premature ventricular contractions occurrence (except Vmax which was decreased by potassium canrenoate during simulated-ischemia). "
5.	Ischemia 01/01/2015 - "Conversely, potassium canrenoate 100 nmol/L and RU 28318 1 μmol/l alone did not affect AP parameters and premature ventricular contractions occurrence (except Vmax which was decreased by potassium canrenoate during simulated-ischemia). "

Related Drugs and Biologics

1.	Spironolactone (Aldactone)
2.	Mineralocorticoids
3.	Mineralocorticoid Receptor Antagonists
4.	Canrenone
5.	Adrenocorticotropic Hormone (ACTH)
6.	prorenoate potassium
7.	Estrogen Receptor Antagonists
8.	Desoxycorticosterone Acetate (DOCA)
9.	Glycyrrhizic Acid (Glycyrrhizin)
10.	Mineralocorticoid Receptors (Mineralocorticoid Receptor)

Related Therapies and Procedures

1.	Intraventricular Infusions
2.	Adrenalectomy
3.	Oral Administration